Polio vaccines are important to prevent the polio disease worldwide

Polio vaccines

Polio vaccines are administered at birth to induce mucosal immunity to the polio virus. The vaccine is effective against all three serotypes of the disease. This method also increases seroconversion rates. It also triggers mucosal protection before enteric pathogens are able to infect the child. It is therefore recommended by the WHO to administer a birth dose of OPV to infants in countries with a high risk of poliomyelitis. The oral poliovirus (OPV) vaccine is the most common vaccine used to eradicate polio in countries. It is easy to administer, is cheap, and induces superior intestinal immunity. The primary difference between the two types of vaccines is that OPV induces intestinal immunity, while IPV induces high transmission immunity to the wild poliovirus. The advantages of both types of vaccines are the same, although IPV is the preferred choice in developed countries.

According to Coherent Market Insights the Polio Vaccines Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028.

Because poliomyelitis is a highly infectious disease, it is imperative that children be immunized. There are 3 strains of the wild poliovirus in the United States. Therefore, it is important for children to be immunized at a young age. The inactivated poliovirus vaccine is based on three wild-type poliovirus strains. It is a live-attenuated vaccine that has the advantage of being oral and not requiring needles. The vaccines are more effective than inactivated ones, but both have their drawbacks. Inactivated vaccines require regular re-administration and must be used by children with weak immune systems. However, there is no reliable proof that either vaccine is effective in the long term.

In the end, a new generation of polio vaccines may be able to eliminate the disease. Adjuvanted IPV type 2 with higher antigen content may provide a more effective primary immunogenicity against type 2. Researchers at Bilthoven Biologicals are developing a new version of m-IPV2 with 32 D-Ag units, which is four times the current dose of type 2 in trivalent IPV.